Effect of BMP-12, TGF-β1 and autologous conditioned serum on growth factor expression in Achilles tendon healing

Knee Surg Sports Traumatol Arthrosc. 2012 Oct;20(10):1907-14. doi: 10.1007/s00167-011-1772-x. Epub 2011 Nov 29.

Abstract

Purpose: Achilles tendon ruptures are devastating and recover slowly and incompletely. There is a great demand for biomolecular therapies to improve recovery, yet little is understood about growth factors in a healing tendon. Here, the role of growth factors during tendon healing in a rat model and their reaction to single and multiple growth factor treatment are explored.

Methods: Rat tendons were transected surgically and resutured. The expression of bFGF, BMP-12, VEGF and TGF-β1 was assessed by immunohistochemical analysis one to 8 weeks after surgery. Paracrine effects of TGF-β1 or BMP-12 added by adenoviral transfer, as well as the effect of autologous conditioned serum (ACS) on growth factor expression, were evaluated.

Results: bFGF, BMP-12 and VEGF expression was highest 1 week after transection. bFGF and BMP-12 declined during the remaining period whereas VEGF expression persisted. TGF-β1 expression dramatically increased after 8 weeks. ACS treatment increased bFGF (P = 0.007) and BMP-12 (P = 0.004) expression significantly after 8 weeks. Also overall expression of bFGF, BMP-12 and TGF-β1 regardless of time point was significantly greater than controls with ACS treatment (P < 0.05). Both BMP-12 and TGF-β1 treatments had no significant effect. No effect was observed in VEGF with any treatment.

Conclusion: bFGF, BMP-12, VEGF and TGF-β1 are differentially expressed during tendon healing. Additional BMP-12 or TGF-β1 has no significant influence, whereas ACS generally increases expression of all factors except VEGF. Staged application of multiple growth factors may be the most promising biomolecular treatment.

Publication types

  • Evaluation Study

MeSH terms

  • Achilles Tendon / drug effects
  • Achilles Tendon / injuries*
  • Achilles Tendon / physiology
  • Animals
  • Biomarkers / metabolism
  • Blood Transfusion, Autologous*
  • Bone Morphogenetic Proteins / genetics
  • Bone Morphogenetic Proteins / metabolism
  • Bone Morphogenetic Proteins / pharmacology*
  • Bone Morphogenetic Proteins / therapeutic use
  • Fibroblast Growth Factor 2 / metabolism
  • Gene Transfer Techniques
  • Growth Differentiation Factors / genetics
  • Growth Differentiation Factors / metabolism
  • Growth Differentiation Factors / pharmacology*
  • Growth Differentiation Factors / therapeutic use
  • Immunohistochemistry
  • Male
  • Models, Animal
  • Rats
  • Rats, Sprague-Dawley
  • Rupture / drug therapy
  • Rupture / metabolism
  • Serum*
  • Tendon Injuries / drug therapy
  • Tendon Injuries / metabolism
  • Tendon Injuries / therapy*
  • Transforming Growth Factor beta1 / genetics
  • Transforming Growth Factor beta1 / metabolism
  • Transforming Growth Factor beta1 / pharmacology*
  • Transforming Growth Factor beta1 / therapeutic use
  • Vascular Endothelial Growth Factor A / metabolism
  • Wound Healing / drug effects*
  • Wound Healing / physiology

Substances

  • Biomarkers
  • Bone Morphogenetic Proteins
  • Gdf7 protein, rat
  • Growth Differentiation Factors
  • Transforming Growth Factor beta1
  • Vascular Endothelial Growth Factor A
  • vascular endothelial growth factor A, rat
  • Fibroblast Growth Factor 2